Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
Stopped early · Phase 1
Conditions studied: Breast Cancer
In brief
RATIONALE: Androgens can cause the growth of breast cancer cells. Hormone therapy using dehydroepiandrosterone (DHEA) may fight breast cancer by blocking the use of androgen by the tumor cells. Letrozole may stop the adrenal glands from making androgens. Giving DHEA together with letrozole may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of DHEA when given together with letrozole in treating patients with metastatic breast cancer.
Key facts
- Study ID
- NCT00516542
- Run by
- OHSU Knight Cancer Institute
- People needed
- 6
- Starts
- 2007-06-01
- Expected to finish
- 2010-12-01
- Last updated by the study team
- 2012-07-24
Who can join
Age: 60 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Knight Cancer Institute at Oregon Health and Science University — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.